Laboratório de Imunomodulação e Novas Abordagens Terapêuticas - LINAT / Núcleo de Pesquisa em Inovação Terapêutica Suely Galdino - NUPIT SG, Universidade Federal de Pernambuco, Recife.
Hospital do Câncer de Pernambuco - HCP, Recife PE, Brazil.
Eur J Histochem. 2021 Mar 4;65(1):3174. doi: 10.4081/ejh.2021.3174.
The sialic acid-binding immunoglobulin-type lectin Siglec-15 is a promising target to cancer immunotherapy in several tumor types. The present study aimed to investigate Siglec-15 expression in gastric cancer (GC) patient tissue and to evaluate its clinical value. Siglec-15 expression was evaluated by immunohistochemistry with 71 patients. Siglec-15 staining was observed in tumor cells of 53 (74.64%) patients, with significant association with histologic classification and angiolymphatic invasion (p<0.05). Immunohistochemistry analysis also detected Siglec-15 in tumor-associated stroma cells (macrophages/myeloid cells). There was no significant association with outcomes parameters. Siglec-15 expression in well differentiated histological GC tissues and in the tumor microenvironment are potential targets to be further investigated as a novel prognostic factor for GC.
唾液酸结合免疫球蛋白型凝集素 Siglec-15 是多种肿瘤类型癌症免疫治疗的一个有前途的靶点。本研究旨在探讨 Siglec-15 在胃癌（GC）患者组织中的表达，并评估其临床价值。通过对 71 例患者进行免疫组织化学分析来评估 Siglec-15 的表达。在 53 例（74.64%）患者的肿瘤细胞中观察到 Siglec-15 染色，其与组织学分类和血管淋巴管浸润显著相关（p<0.05）。免疫组织化学分析还检测到肿瘤相关基质细胞（巨噬细胞/髓样细胞）中的 Siglec-15。但与结局参数无显著相关性。Siglec-15 在组织学上分化良好的 GC 组织和肿瘤微环境中的表达可能是作为 GC 新型预后因素的进一步研究的潜在靶点。
